Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>Events>This Event
  Events - September 2014


Biosimilars and Biobetters

29 Sep 2014 - 30 Sep 2014 - London, UK



Bookmark and Share


The industry leading Biosimilars & Biobetters Conference for combining new biosimilars and biobetter developments with essential networking opportunities, will be taking place in London, on the 29th-30th of September 2014. 

With an in-depth focus on the current and future landscape of the biosimilars market, this year's conference will allow input from key industry experts in the field to engage in meaningful and important discussions on how to accelerate drug development to market.

Join this event and be part of a major networking opportunity providing intimate interaction with your peers, where you will hear case studies, presentations and round table discussions on the key issues surrounding biosimilar commercial and manufacturing developments.

KEY TOPICS INCLUDE:

  • Optimizing the commercial potential of biosimilars in Europe 
  • The big guns are coming! ...how will the entry of originator companies impact the biosimilars industry 
  • What is on the horizon? ... Reviewing the opportunities and challenges for the biopharmaceutical industry 
  • Christening day…but what shall we call you! Discussing the ongoing debate on naming biosimilars... and much more!

KEY SPEAKERS INCLUDE:

  • Alan Sheppard, Global Head Generics, Thought Leadership, IMS Health 
  • Richard Dicicco, Chairman, Harvest Moon Pharmaceuticals 
  • Uwe Gudat, Head of Safety Biosimilars, Merck Switzerland Limited 
  • Catherine Akers, Regulatory Affairs Manager, Amgen Inc  
  • Carsten Brockmeyer, Founder, Formycon AG 
  • Rakesh Dixit, Vice President, R&D, Global Head, Biologics Safety Assessment, Medimmune (AstraZeneca Biologics) 
  • Ineke Braat, CEO, Pan-Generika 
  • Sharma Alok, Principal Scientist & Head Analytical Development, Lupin Laboratories Ltd 
  • Steinar Madsen, Medical Director, Norwegian Medicines Agency 
  • Peter Wittner, Senior Consultant, Interpharm Consultancy 
  • Sarah Faircliffe, Legal Director, Bird & Bird...

Plus, many more at this year's event.

For more information, contact Fateja Begum on +44 (0) 207 827 6184 or e-mail fbegum@smi-online.co.uk

For sponsorship enquiries, contact Alia Malick on +44 (0) 207 827 6168 or e-mail amalick@smi-online.co.uk

Event website: www.smi-online.co.uk/2014biosimilars65.asp



Further information
Scientific News
Drugs that May Combat Deadly Antibiotic-Resistant Bacteria Uncovered
Study identifies 79 compounds that inhibit carbapenem-resistant Enterobacteriaceae (CRE).
Making Precision Medicine a Reality
Researchers are one step closer to understanding the genetic and biological basis of diseases like cancer, diabetes, Alzheimer’s and rheumatoid arthritis – and identifying new drug targets and therapies.
Potential “Good Fat” Biomarker
New method to measure the activity of energy consuming brown fat cells could ease the testing weight loss drugs.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Doubling Down on Dengue
HMS researchers have discovered two ways a compound blocks dengue virus.
Soy Shows Promise as Natural Anti-Microbial Agent
Researchers from University of Guelph show that soy isoflavones and peptides could be used to reduce microbial contamination of food.
AstraZeneca to Sequence 2 Million Genomes in Search for New Drugs
Company launches integrated genomics approach which aims to transform drug discovery and development.
Unique Model for Studying ALS
Unique mouse model will allow researchers to better study the genetic origins and potential treatments of ALS.
Targeting an ‘Undruggable’ Cancer Gene
RAS genes are mutated in more than 30 percent of human cancers and represent one of the most sought-after cancer targets for drug developers.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!